Here at Oxford we are privileged to have a strong portfolio of haematology clinical trials, for a breadth of diseases covering a range of treatments including new types of diagnostic tests, drugs, immune therapies, chemotherapies and treatment regimes. Clinicians work alongside nurses, scientists and statisticians to progress trials efficiently so that effective new treatments can be recommended for consideration within clinical settings.
There are close collaborations with the Oxford Early Phase Clinical Trials Unit and the Late Phase Haematology Unit, so that Oxford patients can take part in phase I, II and III trials, with excellent medical care and close monitoring. Over the last ten years, Oxford consultants have become leading members of national clinical trial groups and are now developing Oxford-led clinical trials, funded both commercially and academically. Clinical trials are open to eligible patients receiving care at the Oxford University Hospitals NHS Trust, and interested patients are advised to speak to their consultant to find out more.
There are currently over 30 active clinical trials coordinated by staff at Oxford Centre for Haematology. Some examples include:
- Clinician Dr Toby Eyre at University of Oxford Hospital heads up European recruiting for a pioneering clinical trial into the use of loxo305 for use in Chronic Lymphoid Leukaemia (CLL) and related non-Hodgkin’s lymphoma (NHL). The BRUIN trial is currently open to UK CLL patients to test the clinical effectiveness of loxo305 compared to current treatment in terms of improved life expectancy and reduced side effects
- Seeking to find better treatments for uncontrolled bleeding which frequently occurs in patients after major trauma haemorrhage, the CRYOSTAT-2 trial is a multi-centre randomised control trial, where Dr Simon Stanworth and team investigate whether the addition of a fibrinogen rich frozen blood plasma component known as cryoprecipitate to blood transfusions will stablise blood clots and reduce bleeding.
- The IMPACT partnership is the UK’s first ever clinical trials partnership dedicated to improving the outcomes of stem cell transplant patients. Headed up by Dr Andy Peniket, ongoing Oxford trials focus on stem cell transplant delivery, crucial in forming the evidence base for new approaches to treatment.
- A current clinical trial with commercial partner Forty Seven Inc is based on studies from Oxford and Stanford on a therapeutic monoclonal antibody against CD47, a universally expressed leukaemia antigen.
- The PROMISE trial sets out to test a new combination therapy of PLX2835 plus ruxolitinib for myelofibrosis patients. This national trial is headed up by Prof Adam Mead and is currently recruiting patients across 15 clinical trial centres in partnership with the Trials Acceleration Programme (TAP) funded by Cure Leukaemia and Cancer Research UK.
Historical haematology clinical trials
An example of a completed blood cancer clinical trial was the CAMELLIA study, which investigated the effects of new treatment called HU5F9-G4 for acute myeloid leukaemia, led by Prof Paresh Vyas.